📊 CYTOF Key Takeaways
Is Altamira Therapeutics Ltd. (CYTOF) a Good Investment?
Altamira Therapeutics presents an extremely high-risk investment profile with complete absence of revenue generation and minimal financial data transparency. The company appears to be in pre-revenue/early-stage development with insufficient public financial disclosures to assess viability, business model, or path to profitability.
Altamira’s fundamentals are very weak: the company remains essentially pre-revenue after the Bentrio divestiture, with recurring operating losses and an SEC-disclosed going-concern warning. While first-half 2025 operating loss improved versus first-half 2024, the improvement was driven partly by lower spending and non-operating finance income rather than durable commercial revenue, and cash fell to just $3.8 thousand as of June 30, 2025.
Why Buy Altamira Therapeutics Ltd. Stock? CYTOF Key Strengths
- Operates in pharmaceutical sector with potential for high-impact therapies
- Listed on OTC exchange indicating some regulatory compliance
- Pre-revenue stage allows for future upside if development succeeds
- Operating loss and operating cash burn improved versus prior-year periods as management reduced R&D and G&A spending
- The company still reported positive shareholders’ equity of about $4.1 million at June 30, 2025
- It retains intangible assets and platform technology exposure that could support partnering or asset monetization
CYTOF Stock Risks: Altamira Therapeutics Ltd. Investment Risks
- Zero revenue and complete lack of profitability metrics indicate non-operational status
- Insufficient financial data disclosed - only 1 metric available suggests inactive SEC filings
- No insider trading activity in past 90 days suggests minimal management confidence
- Pre-revenue biotech firms face extreme development and regulatory risks
- OTC listing limits institutional investment and increases delisting risk
- Inability to assess cash runway, burn rate, or financial runway
- Revenue base is negligible, with 2024 total revenue only about $0.22 million and no evidence of self-sustaining commercialization
- Liquidity is critical: cash and cash equivalents dropped from about $1.0 million at December 31, 2024 to about $3.8 thousand at June 30, 2025 while current liabilities rose to about $2.3 million
- Recurring losses, negative operating cash flow, and explicit substantial doubt about going concern create high financing and dilution risk
Key Metrics to Watch
- Cash and equivalents position and monthly burn rate
- Clinical trial progress and regulatory milestones
- Revenue generation timeline and commercialization updates
- Quarterly cash balance and net cash used in operating activities
- Any meaningful recurring revenue or partnership/licensing cash inflows
Altamira Therapeutics Ltd. (CYTOF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CYTOF Profit Margin, ROE & Profitability Analysis
CYTOF vs Healthcare Sector: How Altamira Therapeutics Ltd. Compares
How Altamira Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Altamira Therapeutics Ltd. Stock Overvalued? CYTOF Valuation Analysis 2026
Based on fundamental analysis, Altamira Therapeutics Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Altamira Therapeutics Ltd. Balance Sheet: CYTOF Debt, Cash & Liquidity
CYTOF Revenue Growth, EPS Growth & YoY Performance
CYTOF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Altamira Therapeutics Ltd. (CIK: 0001601936)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYTOF
What is the AI rating for CYTOF?
Altamira Therapeutics Ltd. (CYTOF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYTOF's key strengths?
Claude: Operates in pharmaceutical sector with potential for high-impact therapies. Listed on OTC exchange indicating some regulatory compliance. ChatGPT: Operating loss and operating cash burn improved versus prior-year periods as management reduced R&D and G&A spending. The company still reported positive shareholders’ equity of about $4.1 million at June 30, 2025.
What are the risks of investing in CYTOF?
Claude: Zero revenue and complete lack of profitability metrics indicate non-operational status. Insufficient financial data disclosed - only 1 metric available suggests inactive SEC filings. ChatGPT: Revenue base is negligible, with 2024 total revenue only about $0.22 million and no evidence of self-sustaining commercialization. Liquidity is critical: cash and cash equivalents dropped from about $1.0 million at December 31, 2024 to about $3.8 thousand at June 30, 2025 while current liabilities rose to about $2.3 million.
What is CYTOF's revenue and growth?
Altamira Therapeutics Ltd. reported revenue of N/A.
Does CYTOF pay dividends?
Altamira Therapeutics Ltd. does not currently pay dividends.
Where can I find CYTOF SEC filings?
Official SEC filings for Altamira Therapeutics Ltd. (CIK: 0001601936) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYTOF's EPS?
Altamira Therapeutics Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYTOF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Altamira Therapeutics Ltd. has a SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYTOF stock overvalued or undervalued?
Valuation metrics for CYTOF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CYTOF stock in 2026?
Our dual AI analysis gives Altamira Therapeutics Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYTOF's free cash flow?
Altamira Therapeutics Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CYTOF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).